Role of the PPAR-α agonist fenofibrate in severe pediatric burn

Burns

Volumn 38, Issue 4, 2012, Pages 481-486

  Elijah, Itoro E ^a   Børsheim, Elisabet ^a   Maybauer, Dirk M ^a,b   Finnerty, Celeste C ^a,c   Herndon, David N ^a   Maybauer, Marc O ^a,b  

^a SHRINERS HOSPITALS FOR CHILDREN   (United States)

^b PHILIPPS UNIVERSITY MARBURG   (Germany)

^c UNIVERSITY OF TEXAS MEDICAL BRANCH   (United States)

Author keywords

Burns; Fenofibrate; Hypermetabolism; Insulin; Lipolysis; PPAR

Indexed keywords

CATECHOLAMINE; CYCLIC AMP; DIACYLGLYCEROL; FENOFIBRATE; G PROTEIN COUPLED RECEPTOR; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INSULIN; METFORMIN; PLACEBO; SIMVASTATIN;

ACUTE KIDNEY FAILURE; APOPTOSIS; BRAIN DAMAGE; BRAIN EDEMA; BURN; DIABETES MELLITUS; DIABETIC PATIENT; DYSLIPIDEMIA; FATTY ACID OXIDATION; FATTY ACID TRANSPORT; GALLSTONE; GASTROINTESTINAL SYMPTOM; GLUCONEOGENESIS; GLUCOSE OXIDATION; GLYCOGENOLYSIS; HEART INFARCTION; HEART VENTRICLE HYPERTROPHY; HEMATOLOGIC DISEASE; HUMAN; HYPERGLYCEMIA; HYPERMETABOLISM; HYPOGLYCEMIA; INSULIN RESISTANCE; INSULIN SENSITIVITY; KIDNEY CELL; LIPOLYSIS; LIPOPROTEIN METABOLISM; LIVER; MITOCHONDRION; NON INSULIN DEPENDENT DIABETES MELLITUS; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; OXIDATIVE STRESS; PEDIATRICS; REVIEW; SIGNAL TRANSDUCTION; SKELETAL MUSCLE; SKIN MANIFESTATION; WOUND HEALING;

BURNS; FENOFIBRATE; HUMANS; HYPERGLYCEMIA; HYPOGLYCEMIC AGENTS; HYPOLIPIDEMIC AGENTS; INSULIN RESISTANCE; LIPID METABOLISM; LIPOLYSIS; PEROXISOME PROLIFERATOR-ACTIVATED RECEPTORS; PPAR ALPHA;

EID: 84859801219     PISSN: 03054179     EISSN: 18791409     Source Type: Journal    
DOI: 10.1016/j.burns.2011.12.004     Document Type: Review

References (48)

1. Weindl G, Schafer-Korting M, Schaller M, Korting HC. Peroxisome proliferator-activated receptors and their ligands: entry into the post-glucocorticoid era of skin treatment? Drugs 2005;65(14):1919-34. (Pubitemid 41324055)
2. Patsouris D, Mandard S, Voshol PJ, Escher P, Tan NS, Havekes LM, et al. PPARalpha governs glycerol metabolism. J Clin Invest 2004;114(1):94-103.
3. Paukkeri EL, Leppanen T, Sareila O, Vuolteenaho K, Kankaanranta H, Moilanen E. PPARalpha agonists inhibit nitric oxide production by enhancing iNOS degradation in LPS-treated macrophages. Br J Pharmacol 2007;152(7):1081-91. (Pubitemid 350166050)
4. Burns KA, Vanden Heuvel JP. Modulation of PPAR activity via phosphorylation. Biochim Biophys Acta 2007;1771(8):952-60. (Pubitemid 47198547)
5. Tzika AA, Mintzopoulos D, Mindrinos M, Zhang J, Rahme LG, Tompkins RG. Microarray analysis suggests that burn injury results in mitochondrial dysfunction in human skeletal muscle. Int J Mol Med 2009;24(3):387-92.
6. Furuhashi M, Ura N, Murakami H, Hyakukoku M, Yamaguchi K, Higashiura K, et al. Fenofibrate improves insulin sensitivity in connection with intramuscular lipid content, muscle fatty acid-binding protein, and betaoxidation in skeletal muscle. J Endocrinol 2002;174(2):321-9. (Pubitemid 34965771)
7. Yoon M. PPARalpha in obesity: sex difference and estrogen involvement. PPAR Res 2010. pii: 584296. Epub 2010 Aug 17.
8. Robinson E, Grieve DJ. Significance of peroxisome proliferator-activated receptors in the cardiovascular system in health and disease. Pharmacol Ther 2009;122(3):246-63.
9. Kliewer SA, Umesono K, Noonan DJ, Heyman RA, Evans RM. Convergence of 9-cis retinoic acid and peroxisome proliferator signalling pathways through heterodimer formation of their receptors. Nature 1992;358(6389):771-4.
10. Sarma S, Ardehali H, Gheorghiade M. Enhancing the metabolic substrate: PPAR-alpha agonists in heart failure. Heart Fail Rev 2012;17(1):35-43.
11. Kraja AT, Province MA, Straka RJ, Ordovas JM, Borecki IB, Arnett DK. Fenofibrate and metabolic syndrome. Endocr Metab Immune Disord Drug Targets 2010;10(2):138-48.
12. Staels B, Maes M, Zambon A. Fibrates and future PPARalpha agonists in the treatment of cardiovascular disease. Nat Clin Pract Cardiovasc Med 2008;5(9):542-53.
13. Moutzouri E, Kei A, Elisaf MS, Milionis HJ. Management of dyslipidemias with fibrates, alone and in combination with statins: role of delayed-release fenofibric acid. Vasc Health Risk Manage 2010;6:525-39.
14. Gauglitz GG, Herndon DN, Jeschke MG. Insulin resistance postburn: underlying mechanisms and current therapeutic strategies. J Burn Care Res 2008;29(5):683-94.
15. Keech A, Simes RJ, Barter P, Best J, Scott R, Taskinen MR, et al. Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial. Lancet 2005;366(9500):1849-61.
16. Ginsberg HN, Elam MB, Lovato LC, Crouse 3rd JR, Leiter LA, Linz P, et al. Effects of combination lipid therapy in type 2 diabetes mellitus. N Engl J Med 2010;362(17): 1563-74.
17. Cree MG, Newcomer BR, Read LK, Sheffield-Moore M, Paddon-Jones D, Chinkes D, et al. Plasma triglycerides are not related to tissue lipids and insulin sensitivity in elderly following PPAR-alpha agonist treatment. Mech Ageing Dev 2007;128(10):558-65. (Pubitemid 47498524)
18. Chew EY, Ambrosius WT, Davis MD, Danis RP, Gangaputra S, Greven CM, et al. Effects of medical therapies on retinopathy progression in type 2 diabetes. N Engl J Med 2010;363(3):233-44.
19. Huang WP, Yin WH, Chen JW, Jen HL, Young MS, Lin SJ. Fenofibrate attenuates endothelial monocyte adhesion in chronic heart failure: an in vitro study. Eur J Clin Invest 2009;39(9):775-83.
20. Besson VC, Chen XR, Plotkine M, Marchand-Verrecchia C. Fenofibrate, a peroxisome proliferator-activated receptor alpha agonist, exerts neuroprotective effects in traumatic brain injury. Neurosci Lett 2005;388(1):7-12. (Pubitemid 41569361)
21. Whitten AE, Lorenz RP, Smith JM. Hyperlipidemiaassociated pancreatitis in pregnancy managed with fenofibrate. Obstet Gynecol 2011;117(2 Pt 2):517-9.
22. Danis R, Akbulut S, Ozmen S, Arikan S. Rhabdomyolysisinduced acute renal failure following fenofibrate therapy: a case report and literature review. Case Report Med 2010. pii: 537818. Epub 2010 Jul 25.
23. Enger C, Gately R, Ming EE, Niemcryk SJ, Williams L, McAfee AT. Pharmacoepidemiology safety study of fibrate and statin concomitant therapy. Am J Cardiol 2010;106(11):1594-601.
24. Finnerty CC, Herndon DN, Przkora R, Pereira CT, Oliveira HM, Queiroz DM, et al. Cytokine expression profile over time in severely burned pediatric patients. Shock 2006;26(1):13-9. (Pubitemid 44297000)
25. Jeschke MG, Chinkes DL, Finnerty CC, Kulp G, Suman OE, Norbury WB, et al. Pathophysiologic response to severe burn injury. Ann Surg 2008;248(3):387-401.
26. Kulp GA, Herndon DN, Lee JO, Suman OE, Jeschke MG. Extent and magnitude of catecholamine surge in pediatric burned patients. Shock 2010;33(4):369-74.
27. Cree MG, Wolfe RR. Postburn trauma insulin resistance and fat metabolism. Am J Physiol Endocrinol Metab 2008;294(1):E1-9.
28. Hart DW, Wolf SE, Chinkes DL, Gore DC, Mlcak RP, Beauford RB, et al. Determinants of skeletal muscle catabolism after severe burn. Ann Surg 2000;232(4):455-65.
29. Jeschke MG, Mlcak RP, Finnerty CC, Norbury WB, Gauglitz GG, Kulp GA, et al. Burn size determines the inflammatory and hypermetabolic response. Crit Care 2007;11(4):R90.
30. Herndon DN, Tompkins RG. Support of the metabolic response to burn injury. Lancet 2004;363(9424):1895-902. (Pubitemid 38748648)
31. Mecott GA, Al-Mousawi AM, Gauglitz GG, Herndon DN, Jeschke MG. The role of hyperglycemia in burned patients: evidence-based studies. Shock 2010;33(1):5-13.
32. Worthley MI, Holmes AS, Willoughby SR, Kucia AM, Heresztyn T, Stewart S, et al. The deleterious effects of hyperglycemia on platelet function in diabetic patients with acute coronary syndromes mediation by superoxide production, resolution with intensive insulin administration. J Am Coll Cardiol 2007;49(3):304-10. (Pubitemid 46097375)
33. Barthel A, Schmoll D. Novel concepts in insulin regulation of hepatic gluconeogenesis. Am J Physiol Endocrinol Metab 2003;285(4):E685-92. (Pubitemid 37176418)
34. Li L, Messina JL. Acute insulin resistance following injury. Trends Endocrinol Metab 2009;20(9):429-35.
35. Morino K, Petersen KF, Shulman GI. Molecular mechanisms of insulin resistance in humans and their potential links with mitochondrial dysfunction. Diabetes 2006;55(Suppl. 2):S9-15.
36. Chang L, Chiang SH, Saltiel AR. Insulin signaling and the regulation of glucose transport. Mol Med 2004;10(7-12): 65-71.
37. Saltiel AR, Pessin JE. Insulin signaling in microdomains of the plasma membrane. Traffic 2003;4(11):711-6. (Pubitemid 37361852)
38. Slavin BG, Ong JM, Kern PA. Hormonal regulation of hormone-sensitive lipase activity and mRNA levels in isolated rat adipocytes. J Lipid Res 1994;35(9):1535-41. (Pubitemid 24291214)
39. Shulman GI. Cellular mechanisms of insulin resistance. J Clin Invest 2000;106(2):171-6. (Pubitemid 30483118)
40. Hart DW, Wolf SE, Mlcak R, Chinkes DL, Ramzy PI, Obeng MK, et al. Persistence of muscle catabolism after severe burn. Surgery 2000;128(2):312-9. (Pubitemid 30622500)
41. Cree MG, Fram RY, Barr D, Chinkes D, Wolfe RR, Herndon DN. Insulin resistance, secretion and breakdown are increased 9 months following severe burn injury. Burns 2009;35(1):63-9.
42. Wolfe RR, Herndon DN, Jahoor F, Miyoshi H, Wolfe M. Effect of severe burn injury on substrate cycling by glucose and fatty acids. N Engl J Med 1987;317(7):403-8. (Pubitemid 17131176)
43. Thyfault JP, Cree MG, Zheng D, Zwetsloot JJ, Tapscott EB, Koves TR, et al. Contraction of insulin-resistant muscle normalizes insulin action in association with increased mitochondrial activity and fatty acid catabolism. Am J Physiol Cell Physiol 2007;292(2):C729-39.
44. Cree MG, Zwetsloot JJ, Herndon DN, Qian T, Morio B, Fram R, et al. Insulin sensitivity and mitochondrial function are improved in children with burn injury during a randomized controlled trial of fenofibrate. Ann Surg 2007;245(2):214-21. (Pubitemid 46148480)
45. Cree MG, Newcomer BR, Herndon DN, Qian T, Sun D, Morio B, et al. PPAR-alpha agonism improves whole body and muscle mitochondrial fat oxidation, but does not alter intracellular fat concentrations in burn trauma children in a randomized controlled trial. Nutr Metab (Lond) 2007;4:9.
46. Murakami K, Tobe K, Ide T, Mochizuki T, Ohashi M, Akanuma Y, et al. A novel insulin sensitizer acts as a coligand for peroxisome proliferator- activated receptoralpha (PPAR-alpha) and PPAR-gamma: effect of PPAR-alpha activation on abnormal lipid metabolism in liver of Zucker fatty rats. Diabetes 1998;47(12):1841-7. (Pubitemid 28549189)
47. Padfield KE, Astrakas LG, Zhang Q, Gopalan S, Dai G, Mindrinos MN, et al. Burn injury causes mitochondrial dysfunction in skeletal muscle. Proc Natl Acad Sci USA 2005;102(15):5368-73. (Pubitemid 40530264)
48. Parihar A, Parihar MS, Milner S, Bhat S. Oxidative stress and anti-oxidative mobilization in burn injury. Burns 2008;34(1):6-17.